[Diffuse large B-cell lymphoma: a single disease?]

Area of Science:

• Oncology
• Hematology

Background:

• Non-Hodgkin's lymphomas are common lymphoid neoplasms.
• Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype, comprising over 60% of cases.
• DLBCL exhibits significant heterogeneity in clinical presentation, genetic makeup, and response to therapy.

Purpose of the Study:

• To enhance progression-free survival, overall survival, and objective response rates in specific DLBCL subgroups.
• To address the challenge of poor treatment response observed in certain DLBCL patient populations.

Main Methods:

• Analysis of clinical, immunohistochemical, and genetic profiles of DLBCL patients.
• Stratification of patients into distinct subgroups based on these profiles.
• Evaluation of existing and novel therapeutic regimens, including R-CHOP and its modifications (R-DA-EPOCH, R2CHOP, IR-CHOP, VR-CHOP, eveRCHOP).

Main Results:

• DLBCL patient subgroups demonstrate differential responses to treatment.
• Certain patient groups show suboptimal outcomes with current therapeutic approaches.
• The study highlights the need for tailored treatment strategies.

Conclusions:

• Personalized treatment programs are crucial for optimizing DLBCL patient outcomes.
• Grouping DLBCL cases based on clinical, immunohistochemical, and genetic profiles is necessary for selecting appropriate therapeutic modalities.
• Novel therapeutic regimens are being developed to improve upon conventional R-CHOP therapy for different risk groups.